Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT04425824 | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2020 |
| clinicaltrials |
| NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma(DR-CHOP) | unknown | Phase 1 / Phase 2 | 58 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 11, 2019 | clinicaltrials |
| NCT02060656 | Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)(LEGEND) | unknown | Phase 2 | 92 | Royal Marsden NHS Foundation TrustOTHER | 1 | Sep 19, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01670370 | Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. | unknown | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 15, 2019 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03719989 | Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(EPIC) | unknown | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT03201471 | Chidamide With R-CHOP Regimen for DLBCL Patients(DLBCL) | unknown | Phase 2 | 39 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03383406 | A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma(IVAM) | unknown | Phase 2 | 30 | Asan Medical CenterOTHER | 0 | Dec 26, 2017 | clinicaltrials |
| NCT02542111 | A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02753647 | Chidamide Plus R-CHOP in Elderly DLBCL | unknown | Phase 2 | 49 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03229616 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT02871869 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 2 / Phase 3 | 316 | Xinjiang Medical UniversityOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02955628 | RICE-ibrutinib in Relapsed DLBCL | unknown | Phase 2 | 34 | Singapore General HospitalOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT01653067 | STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma(STORM) | unknown | Phase 2 | 88 | Mathias Witzens-HarigOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT01279902 | Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL | unknown | Phase 2 | 32 | Asan Medical CenterOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | unknown | Phase 2 | 57 | Pusan National University HospitalOTHER | 0 | Jun 9, 2016 | clinicaltrials |
| NCT02758925 | CyBeR Association in Relapsed/Refractory DLBCL(CyBeR-Lymph) | unknown | Phase 2 | 78 | University Hospital, CaenOTHER | 0 | May 4, 2016 | clinicaltrials |
| NCT02753062 | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma(PTLD) | unknown | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT02388581 | First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL | unknown | Phase 2 | 30 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT01990144 | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01278602 | R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | unknown | Phase 2 | 196 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT01066429 | DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Hospital Universitario Principe de AsturiasOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00333008 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | unknown | Phase 2 | 27 | The Alvin and Lois Lapidus Cancer InstituteOTHER | 1 | Sep 26, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2020source: clinicaltrials